1st December 2022
Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine
Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).
30th November 2022
Phenotypes of Post-COVID-19 Interstitial Lung Disease: Clinical, Radiological and Pathological Correlations
This webinar will discuss the findings of a recent multicenter, prospective study that monitored patients with previous COVID-19 related pneumonia over time to understand the evolution of the disease. The findings of the study and the follow-up which included respiratory function tests, chest CT, and cryobiopsy will be examined and discussed.
25th November 2022
Dilemmas in breast cancer treatment planning: how understanding tumor biology with MammaPrint and BluePrint can help you
This webinar will educate you on how the biology of a breast tumour reveals additional information that can support choosing the best treatment plan. It will specifically focus on now-a-days clinical dilemmas, like what is the best treatment for pre-menopausal patients, what is the optimal duration of endocrine therapy and how can I find those nasty tumours. The dilemmas are discussed with the help of cases.
18th November 2022
BRAF V600E Mutant Metastatic Colorectal Cancer: New Treatment Options and Future Perspectives
Watch this webinar on BRAF V600E mutant metastatic colorectal cancer (mCRC), chaired by therapeutic leaders in the field Professor Fortunato Ciardiello and Professor Chaira Cremolini.
11th November 2022
A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL
Not able to attend the Expert Roundtable Discussion in Paris? Access the on-demand webcast here. This interactive event features expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Topics include: